sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Benzhydrocodone

Medicine

Benzhydrocodone

APADAZ is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • APADAZ should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.
  • APADAZ is a combination of benzhydrocodone, a prodrug of the opioid agonist hydrocodone, and acetaminophen, and is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Do not take if
  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Hypersensitivity to hydrocodone or acetaminophen, or any other component of this product (e.g., anaphylaxis)

What it is used for

Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration reserve APADAZ for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]:

  • Have not been tolerated or are not expected to be tolerated,
  • Have not provided adequate analgesia or are not expected to provide adequate analgesia.

APADAZ should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.

Side effects, and when to stop

The following serious adverse reactions are described, or described in greater detail, in other sections:

  • Addiction, Abuse, and Misuse
  • Life-Threatening Respiratory Depression
  • Interactions with Benzodiazepines and other CNS Depressants
  • Neonatal Opioid Withdrawal Syndrome
  • Hepatotoxicity
  • Opioid-Induced Hyperalgesia and Allodynia
  • Adrenal Insufficiency
  • Severe Hypotension
  • Serious Skin Reactions
  • Gastrointestinal Adverse Reactions
  • Anaphylaxis and Other Hypersensitivity Reactions
  • Seizures
  • Withdrawal

Who should not take it

APADAZ is contraindicated in patients with:

  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Hypersensitivity to hydrocodone or acetaminophen, or any other component of this product (e.g., anaphylaxis)

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Benzhydrocodone; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/benzhydrocodone

APA 7th

sofidex. (2026, August 2). Benzhydrocodone. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/benzhydrocodone

AMA 11th

Benzhydrocodone. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/benzhydrocodone

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.